Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Dr. Jean-Pierre Bizzari

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Dec 14, 2023 7:22pm

161 Views

Post# 35785786

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Dr. Jean-Pierre Bizzari

Thank you AZZAK as IMO I think that this post of yours was one of the best and most realistic that you have posted so thanks for that and GL to all hoping for better times and transparency ahead.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"